GBG Research at SABCS

Clinical trials

Breast Cancer in Pregnancy (BCP) registry (GBG 29), NCT 00196833: oncological management and outcome in young non-pregnant patients with breast cancer

#P1-17-07 Cancer management and outcome of very young non-pregnant patients with breast cancer diagnosed at 40 years or younger–GBG 29

• Session: Poster session 1, Wednesday, December 5, 5:00 pm – 7:00 pm (poster)
• First author: S. Seiler; GBG, Neu-Isenburg, Germany

BMBC registry (GBG 79): validation of a breast-GPA score to estimate the prognosis of breast cancer patients with brain metastases
#P4-08-26 Validation of different prognostic scores in breast cancer patients with brain metastases of the BMBC registry (GBG-79)

• Session: Poster Session 4–Friday, December 7, 7:00 am – 9:00 am (poster)
• First author: ID Witzel, University Medical Center, Hamburg, Germany

KATHERINE (GBG 77), NCT01772472: first results
#GS1-10 Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE

• Session: General Session 1–Hall 3, Wednesday, December 5, 11:00 am (oral presentation)
• First author: CE Geyer Jr., Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA

GeparDouze (GBG 96, NSABP B-59), NCT03281954: trial in progress
#OT3-05-01 A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with Triple Negative Breast Cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze

• Session: Poster Session OT3–Friday, December 7, 5:00 pm – 7:00 pm (poster)
• First author: CE Geyer Jr., Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA

ALEXANDRA/IMpassion030 (GBG 98, BIG 16-05, AFT-27), NCT03498716: trial in progress
#OT3-05-02 ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer

• Session: Poster Session OT3–Friday, December 7, 5:00 pm – 7:00 pm (poster)
• First author: M Ignatiadis, Institut Jules Bordet, Brussels, Belgium

PATINA (GBG 94, AFT-38), NCT02947685: trial in progress
#OT3-02-07 PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

• Session: Poster Session OT3–Friday, December 7, 5:00 pm – 7:00 pm (poster)
• First author: O Metzger, Dana Farber Cancer Institute, Boston, USA

Translational research

GeparNuevo (GBG 89): results of biomarker analyses
#PD2-07 mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)-Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial

• Session: Spotlight Session 5–Thursday, December 6, 5:00 pm – 7:00 pm (poster discussion)
• First author: S. Loibl; GBG, Neu-Isenburg, Germany

#PD5-05 Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial

• Session: Spotlight Session 5–Thursday, December 6, 5:00 pm – 7:00 pm (poster discussion)
• First author: B. Sinn; Institut für Pathologie, Charité-Universitätsmedizin Berlin

#P4-08-26 Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy with durvalumab - Results from the prospectively randomized GeparNuevo trial

• Session: Poster Session 4–Friday, December 7, 7:00 am – 9:00 am (poster)
• First author: C Massa, Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany

Pooled data from the neoadjuvant trials GeparTrio, GeparQuattro, GeparQuinto, GeparSixto and GeparSepto: retrospective analysis to identify factors in predicting relapse despite a pCR in early breast cancer patients
#P2-08-01 Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy – Results of a pooled analysis based on the GBG meta-database

• Session: Poster Session 2–Thursday, December 6, 7:00 am – 9:00 am (poster)
• First author: J. Huober; Universitätsfrauenklinik Ulm, Brustzentrum, Germany

Pooled data from GeparQuinto, GeparSixto and GeparSepto trials: retrospective analysis of hormone receptor phenotype in patients with breast cancer
#P2-08-10 Similarities between low hormone receptor positive and hormone receptor negative breast cancer: An analysis of 4366 patients from multicenter clinical trials

• Session: Poster Session 2–Thursday, December 6, 7:00 am – 9:00 am (poster)
• First author: SL Villegas, Institute of Pathology, Charité Universitätsmedizin Berlin

LEA (GBG 51, GEICAM/2006-11), NCT00545077: pooled data from LEA and C40503 trials
#P2-07-05 A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy

• Session: Poster Session 2–Thursday, December 6, 7:00 am – 9:00 am (poster)
• First author: M-YC Polley, Mayo Clinic, Rochester, MN, USA